How do you treat a patient with widely metastatic, non T790M mutated, EGFR exon 20 insertion mutated lung cancer?

The EGFR exon 20 insertion mutations represent approximately 9% of all EGFR mutations, and affect a similar demographic/clinical group - never/light smokers, adenocarcinoma, tending towards a younger age (Oxnard et al., PMID 23328547). Unfortunately, the data (preclinical and clinical) to date do no...

Aside from poziotinib study, TAK-788 has shown signs of clinical activity in early clinical testing reported in ASCO 2018 (http://abstracts.asco.org/214/AbstView_214_209573.html).

Based on IMPOWER 150 results first reported in late 2017, updated results shown in ASCO 2018 (http://abstracts.asco.org/...

I agree with @Dr. First Last. Patients with EGFR exon 20 mutation tend to have disease that is refractory to 1st and 2nd generation TKIs. There are no standard targeted therapies for this subgroup of patients. I generally treat with standard platinum/pemetrexed chemotherapy or consider a clinical tr...

What a difference 3 years make! Aside from poziotinib and mobocertinib (aka TAK-788), we now also have early data regarding other small molecules in development (CLN-081) and even an EGFR-MET bispecific antibody (amivantamab) showing response rates up to 40% for amivantamab which received US FDA bre...

We currently have data supporting the use of amivantamab in combination with chemotherapy in the first-line setting. The PAPILLON study (Zhou et al., PMID 37870976) showed superior PFS (HR by BICR 0.4, p<0.001) and ORR compared to chemotherapy alone in this patient population. Interim OS analysis re...

Poziotinib trial, if not, chemo therapy.